[2-(Hydroxymethyl)morpholin-4-yl]-piperazin-1-ylphosphinic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: [2-(Hydroxymethyl)morpholin-4-yl]-piperazin-1-ylphosphinic acid
• 英文别名: [2-(hydroxymethyl)morpholin-4-yl]-piperazin-1-ylphosphinic acid
• 化学式: C₉H₂₀N₃O₄P
• 分子量: 265.25
• InChiKey: FVEGYFYLRZNRQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  85.3
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• Methods and compositions for managing vascular conditions
  申请人：Emory University

  公开号：US11149274B2

  公开（公告）日：2021-10-19

  This disclosure relates to methods and compositions for managing vascular conditions by targeting microRNA. In certain embodiments, the disclosure relates to antisense, RNA interference, and blocking oligonucleotide therapeutic compositions and uses related thereto.

  本公开涉及通过靶向 microRNA 治理血管疾病的方法和组合物。 在某些实施方案中，本公开涉及反义、RNA 干扰和阻断寡核苷酸治疗组合物及其相关用途。
• Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors
  申请人：Emory University

  公开号：US11225660B2

  公开（公告）日：2022-01-18

  This disclosure relates to the use of miRNA-483 and its target genes, UBE2C, pVHL and HIF1alpha, in managing the treatment of cardiovascular and inflammatory diseases. In certain embodiments, this disclosure relates to pharmaceutical compositions comprising a miR-483 mimic and/or an HIF inhibitor and a pharmaceutically acceptable excipient for use in treating or preventing a vascular disease or condition. In certain embodiments, the miR-483 mimic is a double stranded nucleobase polymer or an expression vector that expresses mature human miR-483-5p and miR-483-3p sequences or operable fragments and variants.

  本公开涉及 miRNA-483 及其靶基因 UBE2C、pVHL 和 HIF1alpha 在治疗心血管疾病和炎症性疾病中的应用。在某些实施方案中，本公开涉及药物组合物，该组合物包含用于治疗或预防血管疾病或病症的 miR-483 模拟物和/或 HIF 抑制剂和药学上可接受的赋形剂。在某些实施方案中，miR-483模拟物是双链核碱基聚合物或表达成熟人miR-483-5p和miR-483-3p序列或可操作片段和变体的表达载体。
• US20140255927A1
  申请人：——

  公开号：US20140255927A1

  公开（公告）日：2014-09-11
• PURIFICATION OF STEM CELL-DERIVED CARDIOMYOCYTES USING MOLECULAR BEACONS TARGETING CARDIOMYOCYTE SPECIFIC mRNA
  申请人：EMORY UNIVERSITY

  公开号：US20140335606A1

  公开（公告）日：2014-11-13

  This disclosure is in the area of research and therapeutics. In certain embodiments, it provides methods to assist in the purification of cell mixtures, e.g., cardiomyocytes, using molecular beacons targeting cell-type specific RNA, e.g. mRNA.
• METHODS AND COMPOSITIONS FOR MANAGING VASCULAR CONDITIONS
  申请人：GEORGIA TECH RESEARCH CORPORATION

  公开号：US20160002628A1

  公开（公告）日：2016-01-07

  This disclosure relates to methods and compositions for managing vascular conditions by targeting microRNA. In certain embodiments, the disclosure relates to antisense, RNA interference, and blocking oligonucleotide therapeutic compositions and uses related thereto.